Patents by Inventor Jean-Christophe Marine

Jean-Christophe Marine has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210008047
    Abstract: The invention relates to the field of tumor treatment, in particular to melanoma tumor treatment. In particular it relates to the use of retinoid X receptor antagonists for use in tumor treatment, in particular for use in reducing tumor cell heterogeneity during minimal residual disease (MRD), and thus for use in treating MRD. Even more in particular, the invention relates to the use of retinoid X receptor antagonists in combination with clinically established treatments such as treatment with a combination of BRAF and MEK inhibitors, and optionally other anticancer agents.
    Type: Application
    Filed: February 13, 2019
    Publication date: January 14, 2021
    Inventors: Jean-Christophe Marine, Florian Rambow
  • Publication number: 20210010089
    Abstract: The invention relates to the field of tumor disease stratification, in particular melanoma disease stratification. In particular it relates to the methods for tumor analysis, such as for determining tumor cell heterogeneity during treatment. These methods are helpful in selecting or optimizing tumor therapy, or in predicting responses to tumor therapy. The invention further relates to methods for screening for cytotoxic or cytostatic compounds targeting one or more of the heterogeneous tumor cell populations occurring such as during therapy, such as during the minimal residual disease phase.
    Type: Application
    Filed: February 13, 2019
    Publication date: January 14, 2021
    Inventors: Jean-Christophe Marine, Florian Rambow
  • Publication number: 20210008070
    Abstract: The invention relates to the field of tumor treatment, in particular to melanoma tumor treatment. In particular it relates to the use of CD36 antagonists for use in tumor treatment, in particular for use in reducing tumor cell heterogeneity during minimal residual disease (MRD), and thus for use in treating MRD. Even more in particular, the invention relates to the use of CD36 antagonists in combination with clinically established treatments such as treatment with a combination of BRAF and MEK inhibitors, and optionally other anticancer agents.
    Type: Application
    Filed: February 13, 2019
    Publication date: January 14, 2021
    Inventors: Jean-Christophe Marine, Florian Rambow
  • Publication number: 20200392506
    Abstract: The present application relates to the field of cancer, particularly that of cancers with high MDM4 protein levels (such as melanoma, breast, colon or lung cancers, glioblastoma, retinoblastoma, etc.). It is shown herein that direct and selective inhibition of MDM4, e.g., by antisense RNA, leads to growth inhibition of cancer cells and sensitization to chemo or targeted therapies. Also provided are simple ways of determining which patients are most amenable for such treatment by comparing specific transcript levels.
    Type: Application
    Filed: August 21, 2020
    Publication date: December 17, 2020
    Inventors: Jean-Christophe Marine, Ernesto Guccione, Marco Bezzi
  • Patent number: 10767182
    Abstract: The present application relates to the field of cancer, particularly that of cancers with high MDM4 protein levels (such as melanoma, breast, colon or lung cancers, glioblastoma, retinoblastoma, etc.). It is shown herein that direct and selective inhibition of MDM4, e.g., by antisense RNA, leads to growth inhibition of cancer cells and sensitization to chemo or targeted therapies. Also provided are simple ways of determining which patients are most amenable for such treatment by comparing specific transcript levels.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: September 8, 2020
    Assignees: VIB VZW, Katholieke Universiteit Leuven, K.U.Leuven R&D, Agency for Science, Technology and Research
    Inventors: Jean-Christophe Marine, Ernesto Guccione, Marco Bezzi
  • Patent number: 9821004
    Abstract: This disclosure relates to the field of cancer, particularly the field of melanoma. It was found that a particular long non-coding RNA (lncRNA) is specifically up-regulated in melanoma (but not other tumor) cells as compared to melanocytes. Inhibition of this lncRNA in melanoma cells leads to induction of apoptosis and is a novel therapeutic strategy in the treatment of melanoma.
    Type: Grant
    Filed: August 20, 2014
    Date of Patent: November 21, 2017
    Assignees: VIB VZW, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D, UNIVERSITEIT GENT
    Inventors: Jean-Christophe Marine, Eleonora Leucci, Joke Vandesompele, Pieter Mestdagh
  • Publication number: 20170314024
    Abstract: The present application relates to the field of cancer, particularly that of cancers with high MDM4 protein levels (such as melanoma, breast, colon or lung cancers, glioblastoma, retinoblastoma, etc.). It is shown herein that direct and selective inhibition of MDM4, e.g., by antisense RNA, leads to growth inhibition of cancer cells and sensitization to chemo or targeted therapies. Also provided are simple ways of determining which patients are most amenable for such treatment by comparing specific transcript levels.
    Type: Application
    Filed: November 16, 2015
    Publication date: November 2, 2017
    Inventors: Jean-Christophe Marine, Ernesto Guccione, Marco Bezzi
  • Patent number: 9783803
    Abstract: The application relates to the field of cancer, particularly to the field of solid tumors. It was found that a particular long non-coding RNA (lncRNA), NEAT1, an essential architectural component of nuclear paraspeckles, is required for the survival of cancer, but not that of normal, non-transformed, cells. Inhibition of NEAT1 reduces cell viability of cancer cells and induces apoptosis. These data identify NEAT1 as a novel therapeutic target for treatment of solid tumors.
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: October 10, 2017
    Assignees: VIB VZW, Katholieke Universiteit Leuven, K.U. Leuven R&D
    Inventors: Jean-Christophe Marine, Laura Standaert
  • Publication number: 20170009229
    Abstract: The application relates to the field of cancer, particularly to the field of solid tumors. It was found that a particular long non-coding RNA (lncRNA), NEAT1, an essential architectural component of nuclear paraspeckles, is required for the survival of cancer, but not that of normal, non-transformed, cells. Inhibition of NEAT1 reduces cell viability of cancer cells and induces apoptosis. These data identify NEAT1 as a novel therapeutic target for treatment of solid tumors.
    Type: Application
    Filed: February 9, 2015
    Publication date: January 12, 2017
    Inventors: Jean-Christophe Marine, Laura Standaert
  • Publication number: 20160271163
    Abstract: This disclosure relates to the field of cancer, particularly the field of melanoma. It was found that a particular long non-coding RNA (lncRNA) is specifically up-regulated in melanoma (but not other tumor) cells as compared to melanocytes. Inhibition of this lncRNA in melanoma cells leads to induction of apoptosis and is a novel therapeutic strategy in the treatment of melanoma.
    Type: Application
    Filed: August 20, 2014
    Publication date: September 22, 2016
    Inventors: Jean-Christophe Marine, Eleonora Leucci, Joke Vandesompele, Pieter Mestdagh
  • Patent number: 9408885
    Abstract: The present disclosure relates to the field of oncology, more particularly to the field of melanoma. Provided are methods of treating melanoma, particularly advanced cutaneous melanoma, with a combination of pharmaceutical agents comprising MDM4-specific antagonists (such as an inhibitor of the MDM4-p53 interaction or a molecule that decreases MDM4 protein stability) or MDM4-MDM2 dual inhibitors (i.e., molecules that disrupt the interactions between p53 and MDM2 and p53 and MDM4) and one or more chemotherapeutic agents such as for example alkylating agents (i.e., Dacarbazine (DITC) or melphalan), alkylating-like agents (i.e., cisplatin or carboplatin) or mitotic inhibitors (taxanes docetaxel or paclitaxel) and PI3K-AKT, B-RAF and MEK inhibitors. Further provided are pharmaceutical formulations of MDM4-specific antagonists (be it an inhibitor of the MDM4-p53 interaction or a molecule that decreases MDM4 protein stability) or MDM4-MDM2 dual inhibitors (i.e.
    Type: Grant
    Filed: November 29, 2012
    Date of Patent: August 9, 2016
    Assignees: VIB VZW, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D
    Inventor: Jean-Christophe Marine
  • Patent number: 9078895
    Abstract: It has now been found that the p53 pathway is inactivated in ocular cancers such as retinoblastoma. As such, the present invention is a method for inducing ocular cancer cell death using a p53 activator. In particular embodiments, the p53 activator blocks the interaction between DM2 or DMX and p53. As the p53 activator induces ocular cancer cell death, a method for preventing or treating ocular cancer is also provided.
    Type: Grant
    Filed: December 5, 2013
    Date of Patent: July 14, 2015
    Assignees: St. Jude Children's Research Hospital, Flanders Interuniversity Institute for Biotechnology, Universiteit Gent, Leiden University Medical Center
    Inventors: Michael A. Dyer, Jean-Christophe Marine, Aart Gerrit Jochemsen
  • Patent number: 8614192
    Abstract: It has now been found that the p53 pathway is inactivated in ocular cancers such as retinoblastoma. As such, the present invention is a method for inducing ocular cancer cell death using a p53 activator. In particular embodiments, the p53 activator blocks the interaction between DM2 or DMX and p53. As the p53 activator induces ocular cancer cell death, a method for preventing or treating ocular cancer is also provided.
    Type: Grant
    Filed: July 24, 2007
    Date of Patent: December 24, 2013
    Assignees: Leiden University Medical Center, Flanders Interuniversity Institute for Biotechnology, VIB, St. Jude Children's Research Hospital
    Inventors: Michael A. Dyer, Jean-Christophe Marine, Aart Gerrit Jochemsen
  • Publication number: 20130330421
    Abstract: The present disclosure relates to the field of oncology, more particularly to the field of melanoma. Provided are methods of treating melanoma, particularly advanced cutaneous melanoma, with a combination of pharmaceutical agents comprising MDM4-specific antagonists (such as an inhibitor of the MDM4-p53 interaction or a molecule that decreases MDM4 protein stability) or MDM4-MDM2 dual inhibitors (i.e., molecules that disrupt the interactions between p53 and MDM2 and p53 and MDM4) and one or more chemotherapeutic agents such as for example alkylating agents (i.e., Dacarbazine (DITC) or melphalan), alkylating-like agents (i.e., cisplatin or carboplatin) or mitotic inhibitors (taxanes docetaxel or paclitaxel) and PI3K-AKT, B-RAF and MEK inhibitors. Further provided are pharmaceutical formulations of MDM4-specific antagonists (be it an inhibitor of the MDM4-p53 interaction or a molecule that decreases MDM4 protein stability) or MDM4-MDM2 dual inhibitors (i.e.
    Type: Application
    Filed: November 29, 2012
    Publication date: December 12, 2013
    Applicants: KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D, VIB VZW
    Inventor: Jean-Christophe Marine
  • Patent number: 8470785
    Abstract: Compositions and methods for treating ocular cancer are provided. The composition is a subconjunctival formulation of nutlin-3 and its analogs. The composition provides for methods of treating ocular cancer, including retinoblastoma. The formulation has high penetration into ocular tissue with low toxicity.
    Type: Grant
    Filed: September 27, 2011
    Date of Patent: June 25, 2013
    Assignees: St. Jude Children's Research Hospital, Leiden University Medical Center, VIB VZW and Universiteit Gent
    Inventors: Michael A. Dyer, Jean-Christophe Marine, Aart Gerrit Jochemsen, R. Kip Guy, Fangyi Zhu
  • Publication number: 20120115880
    Abstract: Compositions and methods for treating ocular cancer are provided. The composition is a subconjunctival formulation of nutlin-3 and its analogs. The composition provides for methods of treating ocular cancer, including retinoblastoma. The formulation has high penetration into ocular tissue with low toxicity.
    Type: Application
    Filed: September 27, 2011
    Publication date: May 10, 2012
    Applicant: St. Jude Children's Research Hospital
    Inventors: Michael A. Dyer, Jean-Christophe Marine, Aart Gerrit Jochemsen, R. Kip Guy
  • Publication number: 20090298785
    Abstract: It has now been found that the p53 pathway is inactivated in ocular cancers such as retinoblastoma. As such, the present invention is a method for inducing ocular cancer cell death using a p53 activator. In particular embodiments, the p53 activator blocks the interaction between DM2 or DMX and p53. As the p53 activator induces ocular cancer cell death, a method for preventing or treating ocular cancer is also provided.
    Type: Application
    Filed: July 24, 2007
    Publication date: December 3, 2009
    Inventors: Michael A. Dyer, Jean-Christophe Marine, Aart Gerrit Jochemsen
  • Patent number: RE48801
    Abstract: This disclosure relates to the field of cancer, particularly the field of melanoma. It was found that a particular long non-coding RNA (lncRNA) is specifically up-regulated in melanoma (but not other tumor) cells as compared to melanocytes. Inhibition of this lncRNA in melanoma cells leads to induction of apoptosis and is a novel therapeutic strategy in the treatment of melanoma.
    Type: Grant
    Filed: November 20, 2019
    Date of Patent: November 2, 2021
    Assignees: VIB VZW, Katholieke Universiteit Leuven, K.U. Leuven R&D, Universiteit Gent
    Inventors: Jean-Christophe Marine, Eleonora Leucci, Joke Vandesompele, Pieter Mestdagh
  • Patent number: RE48856
    Abstract: The application relates to the field of cancer, particularly to the field of solid tumors. It was found that a particular long non-coding RNA (lncRNA), NEAT1, an essential architectural component of nuclear paraspeckles, is required for the survival of cancer, but not that of normal, non-transformed, cells. Inhibition of NEAT1 reduces cell viability of cancer cells and induces apoptosis. These data identify NEAT1 as a novel therapeutic target for treatment of solid tumors.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: December 21, 2021
    Assignees: VIB VZW, Katholieke Universiteit Leuven, K.U.Leuven R&D
    Inventors: Jean-Christophe Marine, Laura Standaert